Efficacy and prognostic factors of COVID-19 vaccine in patients with hepatocellular carcinoma: Analysis of data from a prospective cohort study.

ABSTRACT:

Background

The efficacy of coronavirus disease 2019 (COVID-19) vaccines in preventing SARS-CoV-2 infection in patients with hepatocellular carcinoma (HCC) is not clear.

Methods

From January 2022 to October 2022, patients diagnosed with HCC in a prospective, multicenter, observational cohort were analyzed.

Results

One hundred and forty-one patients with (n = 107) or without COVID-19 vaccination (n = 34) were included. The number of patients with severe or very severe infection was relatively lower in the vaccinated group (3.7% vs. 11.8%, p = 0.096). Median infection-free survival in the vaccinated group (14.0 vs. 8.3 months, p = 0.010) was significantly longer than that in the unvaccinated group. COVID-19 vaccination (hazard ratio (HR) HR = 0.47), European Cooperative

SUBMITTER: Zhao H 

PROVIDER: S-EPMC11310663 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature